Margarida Maia, PhD,  science writer—

Symdeko (tezacaftor/ivacaftor) favors weight gain, shortens hospital stays, and reduces the number of days on antibiotics in patients with cystic fibrosis (CF), a real-world study of its use at a Scottish clinic reported. However, no significant benefits in patients’ lung function were seen over about a year of…

Sildenafil improves how muscles work when patients with cystic fibrosis (CF) exercise and this translates into better exercise capacity, a new study suggests. The study, “Exercise intolerance in cystic fibrosis: importance of skeletal muscle,” was published in the journal Medicine & Science in Sports &…

Vitamin D intoxication may occur in people with cystic fibrosis (CF) due to accidental errors made by pharmacists in preparing prescriptions, a study has found. Indeed, some 13 patients in the study were taking a dose of vitamin D that was nearly 70 times higher than the prescribed one,…

People with cystic fibrosis (CF) generally are living longer and healthier lives than in the recent past. Now, researchers will conduct a five-year study to look into ways to further increase and improve the lifespan of people with the disease. The idea behind the study comes from a collaborative…

To mark its 10th anniversary, Claire’s Place Foundation has launched a website that seeks to connect the community of people affected by cystic fibrosis (CF). “Our new website is a supportive forum for inspiration as well as a resource to learn about developments in CF, our programs and…

Olgram has raised €1.5 million (about $1.77 million) in seed funding from investors to speed its development of antibiotics to clear persistent bacteria responsible for chronic, repeat infections. The company’s immediate focus is cystic fibrosis (CF), a disease characterized by chronic bacterial infection in the lungs. In a…

Health regulators in Australia have approved Trikafta (elexacaftor/tezacaftor/ivacaftor) to treat people with cystic fibrosis (CF), ages 12 years and older, who have at least one copy of the F508del mutation in the disease-causing gene, Vertex Pharmaceuticals, the therapy’s developer, announced. “We are delighted” that Trikafta is now…

Trikafta, a medication that combines three different therapies (elexacaftor/tezacaftor/ivacaftor), is safe and effective in children with cystic fibrosis (CF) ages 6 to 11 who have certain genetic mutations, results from a Phase 3 clinical trial show. The U.S. Food and Drug Administration (FDA) recently accepted for review a…

Parents of children and young adults with cystic fibrosis (CF) in Ontario sent a video appeal to the head of their province’s government, asking the premier to quickly expand prescription criteria that limits their access to key therapies by Vertex Pharmaceuticals. Two of the three gene modulating treatments noted…

Two bacterial species known to be frequent sources of lung infection in people with cystic fibrosis (CF) — Pseudomonas aeruginosa and Staphylococcus aureus — can feed each other with a nutrient called purine that both need to thrive, a study shows. Such interaction could determine the course of…